A systematic review and meta-analysis of 77 randomized controlled trials involving about 51,000 participants evaluated the effects of SGLT2 inhibitors on the development of urinary tract infections and genital infections in patients with type 2 diabetes; the results highlighted an increased risk of genital infections associated with SGLT2 inhibitors versus the control, but no significant difference related to the risk of urinary tract infections [35]. Here, SLC5A2 is linked to urinary tract infection.